SRX3207

SRX3207 is a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression with IC50 of 39.9 nM. SRX3207 demonstrates efficacy in multiple tumor models and represents a novel combinatorial approach to activate antitumor immunity. SRX3207 potently inhibited Syk and PI3K signaling and augmented the anti-tumor immune response in lung carcinoma tumor model with no toxicity.

Product information

CAS Number: 2254693-15-5

Molecular Weight: 555.65

Formula: C29H29N7O3S

Chemical Name: 3-[4-[[4-[4-(1-Azetidinylmethyl)-3-methyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]phenyl]-5-(4-morpholinyl)-7H-thieno[3, 2-b]pyran-7-one

Smiles: CC1=NN(C=C1CN1CCC1)C1=CC=NC(NC2C=CC(=CC=2)C2=CSC3C(=O)C=C(OC2=3)N2CCOCC2)=N1

InChiKey: ZZVOPDBZUNUMPR-UHFFFAOYSA-N

InChi: InChI=1S/C29H29N7O3S/c1-19-21(16-34-9-2-10-34)17-36(33-19)25-7-8-30-29(32-25)31-22-5-3-20(4-6-22)23-18-40-28-24(37)15-26(39-27(23)28)35-11-13-38-14-12-35/h3-8,15,17-18H,2,9-14,16H2,1H3,(H,30,31,32)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 33 mg/mL(59.38 mM)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

SRX3207 blocks both PI3K and Syk in MΦs thereby activating innate and adaptive antitumor immunity in vivo.

References:

1. Shweta Joshi, et al. Mol Cancer Ther . 2020 Mar;19(3):755-764.

Products are for research use only. Not for human use.